

Welcome and Opening Remarks

Peter LaCamera, MD
Aliaa Barakat, PhD
Rachel Knipe, MD

Welcome



DR. ANDREW TAGER SYMPOSIUM FOR THOSE LIVING WITH IDIOPATHIC PULMONARY FIBROSIS

Friday, October 27, 2017

Welcome to our 8th Symposium

New topics and faculty, while still covering most of the basics — first informal poll ...

Welcome



Key Symposium Principles:

Holistic

Attendee participation a priority

Tailor content to meet needs of diverse audience

Present digestible information

Sensitivity — time, different opinions, varied outcomes

Uplifting

Welcome



Thanks!

Arthur Dea
Aliaa Barakat, PhD

Faculty

Regional Home Care

Boehringer Ingelheim

Welcome



**All We Really Need to Know
We Learned from Andy**



Pulmonary Care and Research Collaborative

Establish a health care and research model for pulmonary diseases that is built on the collaboration of patients, caregivers, physicians and researchers.


Partners in Care Collaborators on Research



ILD Co**o**aborative



Partners in Care Collaborators on Research



Partners in Care Collaborators on Research



Support communication and partnership among patients and physicians

Advance the understanding of the causes and mechanisms of IPF/ILDs

Promote earlier disease recognition

Improve management by both physicians and patients

Partners in Care Collaborators on Research



ILD Collaborative

Physicians

Clinical Data

Patients / Caregivers

Patient Collected/Reported Data

Researchers

Study Data

Open Data Infrastructure: integrates and shares information simply and conveniently, making care and research more accessible and effective

Partners in Care Collaborators on Research



Current Initiatives:

Align management of IPF therapies with patient-important outcomes; optimize treatment in IPF patient populations not studied in clinical trials

Generate real-time data through oxygen therapy

Enhance the care and support of IPF patients and their families

AND Y TAGER

AMTAGER@PARTNERS.ORG

Andrew Tager



Inspiring physician scientist



Andrew Tager



Mentored many young scientists



Andrew Tager




Founded fibrosis research
and clinical centers

ILD Coaborative


A Patient-Physician Collaborative for the
Understanding, Management, and Treatment
of Interstitial Lung Diseases

MGH Andrew M. Tager
Fibrosis Center
(established 2016)

Discovered LPA and S1P: central mediators of lung fibrosis



Discovered LPA causes fibrosis in other organs too





Drugs for IPF in clinical trials thanks to Andy's work

LPA₁ inhibitor

BMS-986020 (Bristol Myer Squibs) Phase 2 finished

CTGF inhibitor

FG-3019 (Fibrogen) Phase 2, 48 weeks reduced
FVC decline

Autotaxin inhibitor

GLPG1690 (Galapagos) Phase 2a, 12 week FVC
stable

S1P₁ agonist (in development)